Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve Outcome
Open Access
- 15 September 2004
- journal article
- clinical trial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (18), 6072-6079
- https://doi.org/10.1158/1078-0432.ccr-04-0654
Abstract
Purpose: More than half of pediatric rhabdomyosarcoma cases have intermediate-risk features and suboptimal outcome (3-year failure-free survival estimates, 55 to 76%). Dose intensification of known active agents may improve outcome.Keywords
This publication has 29 references indexed in Scilit:
- Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young AdultsJournal of Clinical Oncology, 2003
- An analysis of chemotherapy dose and dose-intensity insmall-cell lung cancer: lessons to be drawnAnnals of Oncology, 2002
- Characteristics associated withlong-term progression-free survival following high-dose chemotherapyin metastatic breast cancer and influence of chemotherapy doseAnnals of Oncology, 2002
- The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumoursBritish Journal of Cancer, 2001
- Ifosfamide and Etoposide Are Superior to Vincristine and Melphalan for Pediatric Metastatic Rhabdomyosarcoma When Administered With Irradiation and Combination Chemotherapy: A Report From the Intergroup Rhabdomyosarcoma Study GroupJournal of Pediatric Hematology/Oncology, 2001
- Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantationBone Marrow Transplantation, 2000
- Prognostic Factors in Patients with Localized Ewing’s Sarcoma: The effect on survival of actual received drug dose intensity and of histologic response to induction therapyJournal of Chemotherapy, 1997
- Cyclophosphamide Dose Escalation in Combination with Vincristine and Actinomycin-D (VAC) in Gross Residual SarcomaJournal of Pediatric Hematology/Oncology, 1995
- Dose: A critical factor in cancer chemotherapyAmerican Journal Of Medicine, 1980
- The intergroup rhabdomyosarcoma study (NIH): Objectives and clinical staging classificationJournal of Pediatric Surgery, 1975